Literature DB >> 15601391

Phenomenological features of auditory hallucinations and their symptomatological relevance.

Naoki Hayashi1, Yoshito Igarashi, Kiyoko Suda, Seishu Nakagawa.   

Abstract

Auditory hallucinations include particularly diverse phenomena that reflect various mental functions and pathologies. Their assessment may provide valuable clinical information. This article describes the development of the Matsuzawa Assessment Schedule for Auditory Hallucination (MASAH), which was designed to obtain a broadened view of the phenomena by investigating a wide range of their characteristics. The aim was to identify the basic phenomenological features of auditory hallucinations by performing a factor analytic study of the MASAH ratings of 214 patients with schizophrenia or schizoaffective disorder. Four identified factors were intractability, delusion, influence, and externality, on the basis of which we constructed composite scales that were assumed to represent the features. The correlation analysis of the scales with symptom dimensions derived from the positive and negative syndrome scale verified their clinical relevance. They were also interpretable in terms of human responses to the abnormal experience and some symptom constructs such as delusion and influence experience. It is concluded that the MASAH is an efficient means for evaluating the features, and that this study elicited new understandings of the phenomena such as their multifarious composition and contiguities with other psychotic symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15601391     DOI: 10.1111/j.1440-1819.2004.01316.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  1 in total

1.  Auditory hallucinations in a cross-diagnostic sample of psychotic disorder patients: a descriptive, cross-sectional study.

Authors:  Ann K Shinn; Danielle Pfaff; Sarah Young; Kathryn E Lewandowski; Bruce M Cohen; Dost Öngür
Journal:  Compr Psychiatry       Date:  2011-12-22       Impact factor: 3.735

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.